Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | TESK1 | Q15569 | 1/20 | 0.41 |
| ▸ | TESK2 | Q96S53 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221214 | 0.88 | — | — | |
| SCHEMBL222002 | 0.86 | ABL1 (0.48) | NPC1RAB9ASMN1; SMN2ABL1LIMK1 | |
| SCHEMBL221705 | 0.86 | — | — | |
| SCHEMBL2739748 | 0.81 | ABL1 (0.44) | NPC1RAB9ASMN1; SMN2ABL1LIMK1 | |
| SCHEMBL2739774 | 0.81 | — | — | |
| SCHEMBL2739811 | 0.78 | ABL1 (0.44) | NPC1RAB9ASMN1; SMN2ABL1LIMK1 | |
| SCHEMBL222323 | 0.78 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1502192 | 0.77 | — | — | |
| SCHEMBL2739672 | 0.77 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL2760384 | 0.77 | ABL1 (0.46) | NPC1RAB9ASMN1; SMN2ABL1LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2378/4885RAB9A 3558/4885SMN1; SMN2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.